What Бреинал (Brеinal) Treats: Main Uses and Benefits

Бреинал (Nimodipine) is a specialized medication commonly used in critical care settings to address serious complications that arise following specific types of bleeding on the brain. It is relevant in clinical settings where supportive symptom management for conditions marked by increased physiological stress is appropriate. The drug is used to address symptom patterns and clinical situations where the reduction of ischemic risks is a key therapeutic goal, as part of supportive management in adult patients.

The primary uses are applied in addressing the symptomatic risks associated with Aneurysmal Subarachnoid Hemorrhage (aSAH), including the management of Cerebral Vasospasm and the Delayed Neurological Deficits that can result from it. This supportive therapy is relevant in contexts involving heightened systemic burden. As part of overall care, it is used to address symptoms related to heightened physiological activity. By helping manage symptom patterns associated with acute neurological compromise, it contributes to easing the overall symptom load.

---

Quick Fact: Support in Acute Vascular Events

Feature	Description
Primary Indication	Aneurysmal Subarachnoid Hemorrhage (aSAH)
Symptom Risk Addressed	Delayed Neurological Deficits (DND)
Core Benefit	Assists with maintaining functional stability

Eligibility Scope

Classification	Eligible or Restricted Populations
Populations Allowed	Adult patients with aneurysmal Subarachnoid Hemorrhage (aSAH).
Populations Contraindicated	Patients with known hypersensitivity to the drug or who are concurrently receiving strong CYP3A4-inducing medications, including Rifampicin, Phenobarbital, Phenytoin, or Carbamazepine (as defined in regulatory labeling).
Populations Not Recommended	Use is generally not recommended in patients with Traumatic Subarachnoid Hemorrhage (tSAH) or in nursing mothers, as the drug is known to pass into human milk.

Age and Condition-Specific Eligibility

• Age-Related Rules: Safety and effectiveness have not been established in the pediatric population (patients under 18 years of age). Use in older adults requires caution due to a higher frequency of age-related organ impairment.
• Condition Restrictions: Patients with severe hepatic impairment, particularly liver cirrhosis, are in a restricted-use category. They require close monitoring due to significantly increased drug exposure.
• Physiological Caution: Caution and monitoring are also required for patients with pre-existing hypotension (low blood pressure) or severely raised intracranial pressure.

Connection to the Overall Eligibility Profile

Regulatory documents strictly define eligibility by limiting established use to the adult population with a specific diagnosis and establishing contraindications for hypersensitivity and use with certain enzyme-inducing drugs. The profile further classifies populations with impaired liver function as conditional users who require mandated caution and monitoring.

Interactions with other medicines and products

Official regulatory information regarding interactions with Бреинал (Brеinal) is not specifically detailed in major authoritative government sources such as the FDA or EMA. Consequently, a comprehensive, officially documented interaction profile cannot be provided.

General principles of drug interactions apply, which typically involve pharmacokinetic changes (how the body processes the drug) and pharmacodynamic changes (how the drug affects the body).

Interaction scope is generally summarized into the following domains based on common regulatory practices:

Interaction Domain	Relevant Constraint/Requirement
Drug-Drug Interactions	Potential for altered exposure or effect when co-administered with other prescription or over-the-counter medicines.
Drug-Food Interactions	Risk of altered drug absorption or activity when taken with specific foods or beverages, which may necessitate timing restrictions.
Drug-Supplement Interactions	Possibility of interaction with herbal or dietary supplements, including vitamins, minerals, and botanicals, that may require avoidance or monitoring.

All patients should provide a complete list of all concurrent medications, supplements, and herbal products to a healthcare provider for a thorough review. This practice is essential to prevent potential clinically significant interactions that may affect the safety or effectiveness of treatment.

Molecular Mechanism: Blocking L-type Calcium Channels

The core mechanism of action involves the selective inhibition of Voltage-Gated L-type Calcium Channels ( L-VDCCs). By binding to these channels, Nimodipine prevents the normal influx of extracellular calcium ions ( Ca^2+) into the cell cytoplasm. This molecular action is primarily focused on the smooth muscle lining the blood vessels, inhibiting the steps required for muscle contraction.

---

Physiological Mechanism: Selective Cerebral Vasodilation

Due to its high lipophilicity, Nimodipine efficiently crosses the blood-brain barrier, concentrating its inhibitory effect on the L-VDCCs in the cerebral vasculature. This leads to vasorelaxation and subsequent selective cerebral vasodilation. The physiological consequence is a reduction in cerebral vascular resistance, which alters blood flow to brain tissue.

---

Cellular Effect: Modulation of Calcium Concentration

Beyond vessel relaxation, the action extends to the cellular environment of neurons. The drug attenuates the influx of Ca^2+ into stress-vulnerable neurons, thereby modulating internal calcium concentration. This cellular mechanism contributes to the attenuation of calcium-dependent signaling cascades within these cells.

How to Use Бреинал (Nimodipine): Administration Guidelines

Nimodipine is a highly specialized medication administered via the enteral route (oral or tube), adhering to a strictly defined regimen for the management of aneurysmal subarachnoid hemorrhage (aSAH).

---

Administration Scope and Schedule

Entity	Detail
Route of Administration:	Enteral only (oral swallowing, nasogastric, or gastric tube). Intravenous administration of the oral forms is prohibited.
Standard Dose:	60 mg per administration.
Frequency:	A fixed interval of Every 4 hours (q4h) is required.
Treatment Duration:	Therapy is maintained for 21 consecutive days.
Initiation Timing:	Treatment must begin as soon as possible, ideally within 96 hours of the subarachnoid hemorrhage.

---

Preparation and Special Conditions

Administration must occur on an empty stomach, specifically one hour before or two hours after a meal. This timing is essential for proper use. If the medication is delivered via a feeding tube, the tube must be flushed immediately afterward with a specified volume (e.g., 20 mL) of 0.9% sodium chloride solution. The protocol includes avoiding the consumption of grapefruit juice during the course of therapy.

Population Adjustments

The standard 60 mg dose is reduced to 30 mg every 4 hours for patients who have significant hepatic impairment (liver disease), due to increased drug exposure in this population. The safety and efficacy of Nimodipine have not been established in patients under the age of 18 years.

These instructions define a rigorous, time-dependent protocol, ensuring the medication is administered consistently via the correct route and at the precise dose and timing.

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

Research has evaluated whether the fixed-dose combination drug is associated with different outcomes compared to placebo for changes in acute pain associated with muscle injury. The primary focus of these trials was short-term pain relief over a duration typically limited to seven days.

• Studies investigated whether the drug was associated with a change in pain. Results indicated a statistically significant difference compared to placebo in the Visual Analogue Scale (VAS) pain scores.
• In Phase 3 trials, the combination was associated with changes in pain scores; one study reported a mean change of 50%.

Comparisons to Monotherapy

Findings explored whether the combination had different results than the individual components (Drug A or Drug B) administered alone. This is an important area of research for fixed-dose combinations.

• One study investigated the fixed-dose combination versus the highest approved dose of Drug A alone and Drug B alone. The combination group reported different outcomes than the monotherapy groups.
• The comparison suggested that combining the agents may be associated with different outcomes than either agent alone in the context of acute musculoskeletal pain, although this should be confirmed by further evidence.

Study Limitations

Research on the combination is primarily focused on acute pain. No evidence was found in the examined studies to suggest that the drug is suitable for chronic pain management. Trials did not evaluate effects beyond seven days of administration.

Key Studies & References

1. Efficacy and Safety of the Combination of Diclofenac and Thiocolchicoside in the Treatment of Low Back Pain and Other Conditions: Systematic Review of the Literature
2. Efficacy of Thiocolchicoside for Musculoskeletal Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Common questions about Бреинал (Brеinal) (FAQ)

---

Q: Is Бреинал a stimulant or a "smart drug"?

Official product information classifies Бреинал within the pharmacological group of Calcium Channel Blockers, specifically a dihydropyridine agent. It is structurally and functionally different from central nervous system (CNS) stimulants. Regulatory agencies do not classify this medicine as a controlled substance.

---

Q: What is the difference between how Бреинал works and how supplements work?

Бреинал is a prescription medicine with a strictly defined mechanism of action confirmed by regulatory bodies: it works by blocking L-type calcium channels to achieve selective cerebral vasodilation (widening of blood vessels in the brain). Unlike supplements, this medication's efficacy and safety for its approved use are established through rigorous clinical trials reviewed by governmental agencies.

---

Q: Does the effect of Бреинал last all day, or does it wear off quickly?

Pharmacokinetic data from official documents indicate that the drug is rapidly absorbed and also eliminated from the body relatively quickly. The initial half-life is short. This short half-life is reflected in the administration guidelines, where a fixed interval of every four hours is specified to ensure consistent levels are maintained throughout the treatment course.

---

Q: Are the side effects of Бреинал the same for everyone who takes it?

No. Regulatory documents classify the adverse effects of the medication based on the frequency with which they were observed in clinical trials (for example, Common, Uncommon, or Rare). This classification indicates that the likelihood and severity of side effects can vary significantly between individuals.

---

Q: Is it safe to mix Бреинал with dietary supplements, vitamins, or herbal remedies?

Official information indicates a possibility of interaction with supplements. Certain preparations, such as multivitamins containing minerals, may be associated with a decrease in the medication's intended effects. Official guidance reflects the importance of providing a healthcare provider with a complete list of any supplements being taken for a thorough review.

---

Q: Is there a warning about using Бреинал if I have an existing heart condition?

Caution is indicated in regulatory documents for patients with certain pre-existing conditions. Regulatory warnings advise that blood pressure should be monitored closely, particularly in patients with pre-existing low blood pressure (hypotension) or specific cardiovascular conditions.

---

Q: Is there any research on using Бреинал during pregnancy or while breastfeeding?

Official regulatory materials classify this drug in the FDA Pregnancy Category C. Furthermore, the active ingredient is known to be excreted into human milk, and its use is generally not recommended for mothers who are nursing.

---

Q: Does taking Бреинал affect the results of blood tests or other lab work?

Yes, the medication may be associated with changes in certain laboratory values. Regulatory documents list side effects that include temporary increases in liver enzymes and decreases in platelet count (thrombocytopenia).

---

Q: If I am taking another prescription drug, how can I check for an interaction with Бреинал?

Regulatory documents emphasize the practice of providing a complete list of all concurrent medicines, supplements, and herbal products to a healthcare provider for a thorough review. A medical professional can then thoroughly review this list for any potential clinically significant interactions.

---

Q: Is Бреинал known to be habit-forming or addictive?

According to official regulatory documents from authorities like the US FDA, this medication is not classified as a controlled substance and does not carry an official warning for habit formation or addiction.

---

Q: Will taking Бреинал change my personality or emotional range?

Regulatory information notes that some patients in clinical studies have reported psychiatric adverse reactions. Depression is listed as a common reaction, and alterations in consciousness have also been documented as a nervous system disorder.

---

Q: Is Бреинал a new medication, or has it been used for a long time?

The active ingredient, Nimodipine, has been approved and available for use for many years. While the chemical compound itself is not new, various formulations of the medicine have received regulatory approval at different times, including oral solution forms in recent years.

---

Q: How long does it usually take for Бреинал to start working?

Pharmacokinetic data indicates that the medicine is absorbed relatively quickly after being taken orally. Peak plasma concentrations, which is the point where the drug concentration in the bloodstream is highest, are generally achieved within one hour of administration.

---

Q: Is it normal to feel a change in appetite after starting Бреинал?

A change in appetite is listed in regulatory documents as a possible adverse effect. Specifically, a lack or loss of appetite has been reported as a possible side effect in some patients taking this medicine.

---

Q: Can I miss a dose of Бреинал without causing a major problem?

Official patient instructions detail what to do if an administration is missed. The guidance typically states that if the time for the next scheduled dose is near, the missed dose should be skipped rather than doubled.

---

Q: Can I drink alcohol socially while taking Бреинал?

Alcohol may contribute to additive effects in lowering blood pressure, and official information indicates a need for caution as it may worsen side effects such as feelings of dizziness or faintness.

---

Q: Does Бреинал interact with common antidepressants or anxiety medications?

Regulatory documents identify potential interactions with certain drugs that inhibit the CYP3A4 enzyme system, which is involved in processing this medicine. Specific examples of these inhibitors include certain antidepressants like fluoxetine and nefazodone, and co-administration may lead to increased concentrations of Бреинал in the body.

---

Q: Does Бреинал cause insomnia or trouble sleeping, and if so, why?

Trouble sleeping is listed in regulatory documents as a possible side effect of the medicine. This is classified as an adverse reaction that has been reported in clinical experience.

---

Q: What happens if I stop taking Бреинал suddenly?

Based on available evidence and clinical guidelines, the medication can generally be discontinued suddenly without the need for a gradual reduction (tapering). This applies once the mandated 21-day treatment course is complete or if discontinuation is required for clinical reasons.

---

Q: Can Бреинал affect my ability to drive or operate machinery safely?

The medication may cause dizziness, lightheadedness, or fainting. The potential for these effects means that caution regarding driving or operating machinery is noted in the patient information until the individual understands how the medicine affects them.

Storage Conditions

Storage requirements for Бреинал (Nimodipine) are defined by regulatory labeling to maintain stability. The medicine must be stored at room temperature and protected from freezing. The tablet form should not be stored above 30 C. Due to the light-sensitive nature of the active ingredient, the product must be kept away from light and moisture in its original container, which must be tightly closed.

All forms of the medication must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired medication should be disposed of via an authorized drug take-back program. If a take-back option is unavailable, the product must be disposed of in the household trash after mixing it with an unappealing substance and sealing it, following the non-flush list guidelines from health authorities. Empty packaging requires personal information to be removed before disposal.